Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Sequential Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT06843889Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanfang Hospital, Southern Medical University. Started Apr 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06843889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843889.